Real-World data on tezepelumab for severe asthma: what happens outside trials?

NCT ID NCT06455462

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked back at medical records of 352 adults with severe asthma who started taking tezepelumab in UK hospitals between January 2023 and March 2024. Researchers wanted to see how often patients had asthma attacks and whether they needed oral steroids during the year after starting the drug. Because it's an observational study, it doesn't test the drug but describes what happens in real-world care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tezepelumab
What this could lead to: If the results show tezepelumab works well in real-world settings, it could support its use as a standard treatment for severe asthma.
What could go wrong: This is a retrospective chart review, not a controlled trial, so it can't prove cause and effect. Results may be influenced by how doctors chose patients for treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma chronic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEVERE ASTHMA

Contacts and locations

Locations

Research Site

Birmingham, United Kingdom
Research Site

Liverpool, United Kingdom
Research Site

London, United Kingdom
Research Site

Newcastle, United Kingdom
Research Site

Plymouth, United Kingdom
Research Site

Southampton, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.